Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors.

Journal of hematology & oncology·2026

Same author

Cross-priming underlies the efficacy of antibody-drug conjugates and immunotherapy combinations.

Trends in immunology·2026

Same author

Monomethyl-auristatin E-based anti-CD137 (4-1BB) antibody drug conjugates are not suitable tools to deplete activated T lymphocytes.

Immunobiology·2026

Same author

First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors.

Journal for immunotherapy of cancer·2026

Same author

Engineering and improving anti-CTLA-4 checkpoint inhibitors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Conventional type-1 DC density is associated with checkpoint inhibitor response across multiple types of cancer.

The Journal of clinical investigation·2026

Search research articles

Related Experiment Video

Updated: Dec 7, 2025

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

Interleukin-12 Message in a Bottle.

Assunta Cirella^1,2, Pedro Berraondo^1,2,3, Claudia Augusta Di Trani^1,2

¹Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research

|October 2, 2020

Summary

Local gene transfer using lipid-nanoparticle mRNA effectively delivers interleukin-12 (IL12) for cancer immunotherapy in mouse models. This approach confines IL12 expression to tumors, enhancing efficacy and avoiding systemic toxicity, paving the way for clinical trials.

More Related Videos

Accurate and Simple Measurement of the Pro-inflammatory Cytokine IL-1β using a Whole Blood Stimulation Assay

Accurate and Simple Measurement of the Pro-inflammatory Cytokine IL-1β using a Whole Blood Stimulation Assay

Published on: March 1, 2011

Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells

Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells

Published on: May 22, 2014

Related Experiment Videos

Last Updated: Dec 7, 2025

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

Accurate and Simple Measurement of the Pro-inflammatory Cytokine IL-1β using a Whole Blood Stimulation Assay

Accurate and Simple Measurement of the Pro-inflammatory Cytokine IL-1β using a Whole Blood Stimulation Assay

Published on: March 1, 2011

Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells

Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells

Published on: May 22, 2014

Area of Science:

Oncology
Immunotherapy
Gene Therapy
Nanotechnology

Background:

Interleukin-12 (IL12) is a potent immunotherapy agent for cancer.
Systemic administration of IL12 leads to toxicity.
Local gene transfer offers a strategy to target IL12 delivery to tumors.

Purpose of the Study:

To evaluate the efficacy and safety of local gene transfer for IL12 delivery.
To assess the potential of lipid-nanoparticle mRNA technology for cancer immunotherapy.

Main Methods:

Utilized lipid-nanoparticle mRNA to achieve local expression of IL12.
Tested the approach in preclinical mouse models of cancer.

Main Results:

Demonstrated successful IL12 expression and therapeutic efficacy in mouse models.
Confirmed that local delivery minimizes systemic toxicity associated with IL12.

Conclusions:

Lipid-nanoparticle mRNA mediated local IL12 gene transfer is a promising strategy for cancer immunotherapy.
This approach overcomes the safety challenges of systemic IL12 administration.
The findings support the initiation of clinical trials for this novel therapy.